Natalizumab in acute ischemic stroke (ACTION II): A randomized, placebo-controlled trial
Mitchell S V Elkind, Roland Veltkamp, Joan Montaner, S Claiborne Johnston, Aneesh B Singhal, Kyra Becker, Maarten G Lansberg, Weihua Tang, Rachna Kasliwal, Jacob Elkins, Mitchell S V Elkind, Roland Veltkamp, Joan Montaner, S Claiborne Johnston, Aneesh B Singhal, Kyra Becker, Maarten G Lansberg, Weihua Tang, Rachna Kasliwal, Jacob Elkins
Abstract
Objective: We evaluated the effect of 2 doses of natalizumab on functional outcomes in patients with acute ischemic stroke (AIS).
Methods: In this double-blind phase 2b trial, patients with AIS aged 18-80 years with NIH Stroke Scale scores of 5-23 from 53 US and European sites were randomized 1:1:1 to receive a single dose of 300 or 600 mg IV natalizumab or placebo, with randomization stratified by treatment window (≤9 or >9 to ≤24 hours from patient's last known normal state). The primary endpoint was a composite measure of excellent outcome (modified Rankin Scale score ≤1 and Barthel Index score ≥95) at day 90 assessed in all patients receiving a full dose. Sample size was estimated from a Bayesian model; p values were not used for hypothesis testing.
Results: An excellent outcome was less likely with natalizumab than with placebo (natalizumab 300 or 600 mg odds ratio 0.60; 95% confidence interval 0.39-0.93). There was no effect modification by time to treatment or use of thrombolysis/thrombectomy. For natalizumab 300 mg, 600 mg, or placebo, there were no differences in incidence of adverse events (90.0%, 92.1%, and 92.3%, respectively), serious adverse events (25.6%, 32.6%, and 20.9%, respectively), or deaths (6.7%, 4.5%, and 5.5%, respectively).
Conclusions: Natalizumab administered ≤24 hours after AIS did not improve patient outcomes.
Clinicaltrialsgov identifier: NCT02730455 CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that for patients with AIS, an excellent outcome was less likely in patients treated with natalizumab than with placebo.
Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
Figures
References
- Chamorro A, Meisel A, Planas AM, Urra X, van de Beek D, Veltkamp R. The immunology of acute stroke. Nat Rev Neurol 2012;8:401–410.
- Hurn PD, Subramanian S, Parker SM, et al. . T- and B-cell-deficient mice with experimental stroke have reduced lesion size and inflammation. J Cereb Blood Flow Metab 2007;27:1798–1805.
- Yilmaz G, Arumugam TV, Stokes KY, Granger DN. Role of T lymphocytes and interferon-gamma in ischemic stroke. Circulation 2006;113:2105–2112.
- Becker K, Kindrick D, Relton J, Harlan J, Winn R. Antibody to the alpha4 integrin decreases infarct size in transient focal cerebral ischemia in rats. Stroke 2001;32:206–211.
- Langhauser F, Kraft P, Gob E, et al. . Blocking of alpha4 integrin does not protect from acute ischemic stroke in mice. Stroke 2014;45:1799–1806.
- Liesz A, Zhou W, Mracsko E, et al. . Inhibition of lymphocyte trafficking shields the brain against deleterious neuroinflammation after stroke. Brain 2011;134:704–720.
- Neumann J, Riek-Burchardt M, Herz J, et al. . Very-late-antigen-4 (VLA-4)-mediated brain invasion by neutrophils leads to interactions with microglia, increased ischemic injury and impaired behavior in experimental stroke. Acta Neuropathol 2015;129:259–277.
- Llovera G, Hofmann K, Roth S, et al. . Results of a preclinical randomized controlled multicenter trial (pRCT): anti-CD49d treatment for acute brain ischemia. Sci Transl Med 2015;7:299ra121.
- Rudick RA, Sandrock A. Natalizumab: α4-integrin antagonist selective adhesion molecule inhibitors for MS. Expert Rev Neurother 2004;4:571–580.
- Polman CH, O'Connor PW, Havrdova E, et al. . A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354:899–910.
- Tysabri® (natalizumab) [prescribing information]. Cambridge, MA: Biogen; 2018.
- Miller DH, Khan OA, Sheremata WA, et al. . A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003;348:15–23.
- Kirveskari J, Bono P, Granfors K, Leirisalo-Repo M, Jalkanen S, Salmi M. Expression of alpha4-integrins on human neutrophils. J Leukoc Biol 2000;68:243–250.
- Relton JK, Sloan KE, Frew EM, Whalley ET, Adams SP, Lobb RR. Inhibition of alpha4 integrin protects against transient focal cerebral ischemia in normotensive and hypertensive rats. Stroke 2001;32:199–205.
- Elkins J, Veltkamp R, Montaner J, et al. . Safety and efficacy of natalizumab in patients with acute ischaemic stroke (ACTION): a randomised, placebo-controlled, double-blind phase 2 trial. Lancet Neurol 2017;16:217–226.
- Lyden P, Lu M, Jackson C, et al. . Underlying structure of the National Institutes of Health Stroke Scale: results of a factor analysis. NINDS tPA Stroke Trial Investigators. Stroke 1999;30:2347–2354.
- Sulter G, Steen C, De Keyser J. Use of the Barthel index and modified Rankin scale in acute stroke trials. Stroke 1999;30:1538–1541.
- National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581–1587.
- Duncan PW, Lai SM, Bode RK, Perera S, DeRosa J. Stroke Impact Scale–16: a brief assessment of physical function. Neurology 2003;60:291–296.
- Chiti G, Pantoni L. Use of Montreal Cognitive Assessment in patients with stroke. Stroke 2014;45:3135–3140.
- Hacke W, Kaste M, Bluhmki E, et al. . Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008;359:1317–1329.
- Shuaib A, Lees KR, Lyden P, et al. . NXY-059 for the treatment of acute ischemic stroke. N Engl J Med 2007;357:562–571.
- Albers GW, von Kummer R, Truelsen T, et al. . Safety and efficacy of desmoteplase given 3-9 h after ischaemic stroke in patients with occlusion or high-grade stenosis in major cerebral arteries (DIAS-3): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet Neurol 2015;14:575–584.
- Lees KR, Zivin JA, Ashwood T, et al. . NXY-059 for acute ischemic stroke. N Engl J Med 2006;354:588–600.
- Enlimomab Acute Stroke Trial Investigators. Use of anti-ICAM-1 therapy in ischemic stroke: results of the Enlimomab Acute Stroke Trial. Neurology 2001;57:1428–1434.
- Furuya K, Takeda H, Azhar S, et al. . Examination of several potential mechanisms for the negative outcome in a clinical stroke trial of enlimomab, a murine anti-human intercellular adhesion molecule-1 antibody: a bedside-to-bench study. Stroke 2001;32:2665–2674.
- Veltkamp R, Gill D. Clinical trials of immunomodulation in ischemic stroke. Neurotherapeutics 2016;13:791–800.
- Doyle KP, Quach LN, Sole M, et al. . B-lymphocyte-mediated delayed cognitive impairment following stroke. J Neurosci 2015;35:2133–2145.
- Gill D, Veltkamp R. Dynamics of T cell responses after stroke. Curr Opin Pharmacol 2016;26:26–32.
- Liu Z, Chopp M. Astrocytes, therapeutic targets for neuroprotection and neurorestoration in ischemic stroke. Prog Neurobiol 2016;144:103–120.
- Amantea D, Greco R, Micieli G, Bagetta G. Paradigm shift to neuroimmunomodulation for translational neuroprotection in stroke. Front Neurosci 2018;12:241.
Source: PubMed